Raymond James Financial Services Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-5,396
| Closed | -$491K | – | 3378 |
|
|
2023
Q1 | $491K | Buy |
+5,396
| New | +$491K | ﹤0.01% | 2355 |
|
|
2021
Q4 | – | Sell |
-2,458
| Closed | -$247K | – | 3375 |
|
|
2021
Q3 | $247K | Buy |
2,458
+206
| +9% | +$20.7K | ﹤0.01% | 2823 |
|
|
2021
Q2 | $319K | Sell |
2,252
-399
| -15% | -$56.5K | ﹤0.01% | 2672 |
|
|
2021
Q1 | $264K | Buy |
2,651
+850
| +47% | +$84.6K | ﹤0.01% | 2712 |
|
|
2020
Q4 | $223K | Buy |
+1,801
| New | +$223K | ﹤0.01% | 2646 |
|
|
2020
Q3 | – | Sell |
-2,175
| Closed | -$339K | – | 2947 |
|
|
2020
Q2 | $339K | Buy |
+2,175
| New | +$339K | ﹤0.01% | 2159 |
|